Drug intelligence / Profile preview

nanocovax

Development stage: Phase 3
Lead developer: Nanogen
Modality: Recombinant Proteins and Enzymes, Vaccines & Immunotherapeutics
Administration: Intramuscular

Overview

Nanocovax is a recombinant protein subunit vaccine developed for the prevention of COVID-19. It consists of the extracellular (soluble) portion of the SARS-CoV-2 spike (S) protein, produced in Chinese hamster ovary (CHO) cells and formulated with an aluminum hydroxide adjuvant. The vaccine is administered intramuscularly in two doses, 28 days apart. Nanocovax induces high levels of S protein-specific IgG and neutralizing antibodies, demonstrating robust immunogenicity and safety in preclinical animal models as well as human clinical trials. The immune response is characterized by a Th2 polarization, consistent with the use of an aluminum adjuvant[1][3][4][5].

Brand names: nanocovax

Targets

SARS-CoV-2 spike

Beyond the preview

Go deeper on nanocovax.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on nanocovax.

Explore the full profile